Table 1 Patient characteristics
From: Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
All patients (n = 74) | UTUC (n = 34) | UBUC (n = 40) | |
|---|---|---|---|
Age, years | |||
Median | 64 | 65 | 64 |
Range | 37 to 83 | 50 to 79 | 37 to 83 |
Gender | |||
Male | 64 (86%) | 25 (74%) | 37 (93%) |
Female | 10 (14%) | 9 (26%) | 3 (8%) |
pT | |||
1 | 3 (4%) | 1 (3%) | 2 (5%) |
2 | 14 (19%) | 5 (15%) | 9 (23%) |
3 | 55 (74%) | 27 (79%) | 28 (70%) |
4 | 2 (3%) | 1 (3%) | 1 (3%) |
pN | |||
0 | 11 (15%) | 7 (21%) | 4 (10%) |
1 | 19 (26%) | 4 (12%) | 15 (38%) |
2 | 23 (31%) | 6 (18%) | 17 (43%) |
3 | 4 (5%) | 1 (3%) | 3 (8%) |
Not evaluated | 17 (23%) | 16 (47%) | 1 (3%) |
Grade | |||
2 | 20 (27%) | 11 (32%) | 9 (23%) |
3 | 54 (73%) | 23 (68%) | 31 (78%) |
Lymphovascular invasion | |||
No | 34 (46%) | 15 (44%) | 19 (48%) |
Present | 40 (54%) | 19 (56%) | 21 (53%) |
Type of surgery | |||
Open | 41 (55%) | 15 (44%) | 26 (65%) |
Laparoscopic/robot-assisted | 33 (45%) | 19 (56%) | 14 (35%) |
Perioperative chemotherapy | |||
None | 21 (28%) | 10 (29%) | 11 (28%) |
Neoadjuvant | 27 (36%) | 1 (3%) | 26 (65%) |
Adjuvant | 26 (35%) | 23 (68%) | 3 (8%) |